Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

December 18, 2019

Study Completion Date

December 23, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

Hypidone Hydrochloride tablets

Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks

OTHER

Placebo

Placebo tablets will be given orally, twice daily, for 6 weeks

Trial Locations (19)

200030

Shanghai Mental Health Center, Shanghai

Unknown

Beijing Anding Hospital, Capital Medical University, Beijing

Beijing Huilongguan Hospital, Beijing

Peking University Sixth Hospital, Beijing

Guangzhou Hui'ai Hospital, Guangzhou

Hebei Mental Health Center, Baoding

Henan Psychiatric Hospital, Xinxiang

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Wuhan Mental Health Center, Wuhan

Nanjing Brain Hospital, Nanjing

Wuxi Mental Health Center, Wuxi

Jiangxi Mental Hospital, Nanchang

Jilin Neuropsychiatric Hospital, Siping

Shandong Mental Health Center, Jinan

Xi'an Mental Health Center, Xi’an

The 7th People's Hospital of Hangzhou, Hangzhou

the First Affiliated Hospital of Zhejiang University, Hangzhou

The Third People's Hospital of Huzhou, Huzhou

Ningbo Kangning Hospital, Ningbo

All Listed Sponsors
lead

Zhejiang Huahai Pharmaceutical Co., Ltd.

INDUSTRY

NCT03739632 - Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets | Biotech Hunter | Biotech Hunter